What is Galventa?
Galventa, based in Saint Gallen, Switzerland, is a pioneering entity leveraging advanced galenic platform technologies. The company is dedicated to the development of innovative nutraceutical and pharmaceutical products, positioning itself at the forefront of health and wellness solutions. Its focus on cutting-edge development suggests a company in a scaling phase, aiming to translate its technological prowess into market-ready offerings.
How much funding has Galventa raised?
Galventa has raised a total of $809K across 1 funding round:
Angel/Seed
$809K
Angel/Seed (2021): $809K with participation from Gen Ilac
Key Investors in Galventa
Gen Ilac
Gen Ilac is an investor participating in the funding round, with its specific focus area not detailed.
What's next for Galventa?
With a substantial enterprise-level funding context and a recent strategic investment, Galventa is poised for accelerated growth and market expansion. The capital infusion is expected to fuel further research and development, enhance production capabilities, and potentially broaden its product portfolio. This strategic backing signals confidence from investors in Galventa's unique technological approach and its potential to disrupt the nutraceutical and pharmaceutical sectors.
See full Galventa company page
